^{Sarawak General Hospital received the award for Top Study Site in Ministry of Health for Sponsored Research in early May this year.}


KUCHING, Oct 10 (Bernama) -- Sarawak General Hospital (SGH), together with its Clinical Research Centre (CRC) celebrated a series of significant milestones in early phase clinical research, positioning itself as a key player in the global First-in-Human (FIH) clinical trial landscape. These achievements highlighted SGH’s growing reputation as a regional contender in early phase research and its excellent delivery of international sponsored studies.

Among the most recent accomplishments was the successful enrolment of the first patient in the Asia Pacific region for a new treatment in Systemic Lupus Erythematosus (SLE), an autoimmune condition that affects joints, skin, brain, lungs, kidneys, and blood vessels. The industry-sponsored FIH clinical trial was led by SGH’s Consultant Rheumatologist, Dr Teh Cheng Lay.

Sarawak General Hospital was the first centre in Malaysia to have conducted a FIH clinical trial.  In 2023, SGH conducted a first-in-class FIH clinical trial for patients with advanced solid tumours, led by Dr Voon Pei Jye, Consultant Medical Oncologist.  Findings from this study were featured in the AACR-NCI-EORTC International Conference at Boston whereby Dr Voon became the first Malaysian to co-author a FIH global multicentre clinical trial, placing Malaysia alongside world top-ranking cancer institutes. Subsequently, a groundbreaking FIH study for advanced solid tumours was conducted, again led by Dr Voon. The study marked a historic moment earlier this July, having successfully enrolled the first patient in Malaysia.

Sarawak General Hospital’s early phase accomplishments began as early as 2021, with its Consultant Haematologist, Dr Chew Lee Ping being named the first Global Recruiter for a First-in-Patient study. Since then, the nation’s early phase clinical research capabilities have been running strong. Much of this is owed through Clinical Research Malaysia’s Phase 1 Realisation Project which enabled the nation’s early phase ecosystem from the establishment of guidelines to human capability development, as well as the establishment of the Phase 1 facility in CRC SGH.

Three more upcoming FIH oncology studies from global multinational pharmaceuticals are slated for SGH, focused on treatments for solid tumours, non-small cell lung cancer and prostate cancer. With many accomplishments under its belt, Sarawak General Hospital remains to be among the nation’s top clinical research site that have significantly contributed to the global advancement of therapeutics.


About Clinical Research Malaysia (CRM) 
Clinical Research Malaysia (CRM) is a Global Trusted Research Management Organisation established by the Ministry of Health Malaysia in 2012. The organisation is guided by the principles of Humanity, Stability and Sustainability in providing global clinical trial solutions and enabling a thriving clinical research ecosystem in the country. At its very core, CRM aims to bring clinical research that addresses the unmet needs of patients and transforms health outcomes in Malaysia. 

CRM delivers sponsored clinical trials with Speed, Reliability and Quality through operational excellence and working with stakeholders by providing end-to-end clinical research support services. Certified with both ISO 9001:2015 (Quality Management System) and ISO 37001:2016 (Anti-Bribery Management System), and being aligned to international regulations, our core values and code of conduct are ingrained throughout CRM. The strength of this organisation lies in the people of CRM as we strive in our vision to make Malaysia the preferred clinical research hub in Asia. https://clinicalresearch.my   
 

SOURCE :  Clinical Research Malaysia (CRM) 

FOR MORE INFORMATION, PLEASE CONTACT:
Name : Siti Nazatul Tokshim
Corporate Communications Executive    
Email : siti.nazatul@clinicalresearch.my
Tel : +6019-784 2080 / +603-7931 5566 (ext. 123)

--BERNAMA